

Special Issue

Advances in Non-Coding RNAs as Prognostic Biomarkers, Therapeutic Targets, and Regulatory Mechanisms in Cancer

Message from the Guest Editors

This Special Issue aims to highlight recent progress and emerging concepts in the rapidly expanding field of non-coding RNAs (ncRNAs), with a particular focus on their roles in cancer biology and their potential clinical applications. In recent years, the scientific community has uncovered the vast complexity and functional significance of ncRNAs, including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs). These molecules have been shown to influence critical processes such as tumor initiation, progression, metastasis, therapy resistance, and immune regulation. As a result, ncRNAs are gaining increasing attention as both biomarkers for early diagnosis and prognosis, and as promising therapeutic targets. This Special Issue welcomes original research articles and reviews addressing the multifaceted roles of ncRNAs in cancer. Topics of interest include molecular mechanisms of action, functional characterization, clinical correlations, biomarker discovery, and ncRNA-based therapeutic strategies. We look forward to receiving your contributions and to showcasing the latest advances in this dynamic and promising area of cancer research.

Guest Editors

Dr. Pablo Pérez-Moreno

Programa de Comunicación Celular en Cáncer, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

Dr. Juan Pablo Muñoz

Biochemistry Laboratory, Department of Chemistry, Faculty of Sciences, University of Tarapacá, Arica, Chile

Deadline for manuscript submissions

25 December 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/240916

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)